Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 97

Related Citations for PubMed (Select 23153897)

1.

The effect of immediate postpartum depot medroxyprogesterone on early breastfeeding cessation.

Brownell EA, Fernandez ID, Fisher SG, Howard CR, Ternullo SR, Lawrence RA, Duckett JW, Dozier AM.

Contraception. 2013 Jun;87(6):836-43. doi: 10.1016/j.contraception.2012.08.045. Epub 2012 Nov 12.

2.

Patterns of postpartum depot medroxyprogesterone administration among low-income mothers.

Dozier AM, Nelson A, Brownell EA, Howard CR, Lawrence RA.

J Womens Health (Larchmt). 2014 Mar;23(3):224-30. doi: 10.1089/jwh.2012.4016. Epub 2014 Jan 20.

3.

Early experience with the contraceptive use of depot medroxyprogesterone acetate in an inner-city clinic population.

Polaneczky M, Guarnaccia M, Alon J, Wiley J.

Fam Plann Perspect. 1996 Jul-Aug;28(4):174-8.

PMID:
8853283
4.

The discordance between planned use and actual receipt of immediate postpartum depot medroxyprogesterone among low-income women.

Brownell EA, Lussier MM, Dozier AM, Howard CR, Fisher SG, Duckett JW, Lawrence RA, Fernandez ID.

Breastfeed Med. 2014 Jul-Aug;9(6):290-3. doi: 10.1089/bfm.2013.0112. Epub 2014 Jun 3.

PMID:
24893264
5.

Labor epidural anesthesia, obstetric factors and breastfeeding cessation.

Dozier AM, Howard CR, Brownell EA, Wissler RN, Glantz JC, Ternullo SR, Thevenet-Morrison KN, Childs CK, Lawrence RA.

Matern Child Health J. 2013 May;17(4):689-98. doi: 10.1007/s10995-012-1045-4.

6.

Hormonal contraceptive use and discontinuation among HIV-infected women in Uganda and Zimbabwe.

Bengtson A, Kwok C, Salata RA, Byamugisha J, Chipato T, Rwambuya S, Moyo P, Morrison CS.

J Acquir Immune Defic Syndr. 2013 Aug 1;63(4):506-13. doi: 10.1097/QAI.0b013e318293df9e.

7.

Use of depot medroxyprogesterone acetate contraception and incidence of bone fracture.

Lanza LL, McQuay LJ, Rothman KJ, Bone HG, Kaunitz AM, Harel Z, Ataher Q, Ross D, Arena PL, Wolter KD.

Obstet Gynecol. 2013 Mar;121(3):593-600. doi: 10.1097/AOG.0b013e318283d1a1.

PMID:
23635623
8.

Early weight gain related to later weight gain in adolescents on depot medroxyprogesterone acetate.

Bonny AE, Secic M, Cromer B.

Obstet Gynecol. 2011 Apr;117(4):793-7. doi: 10.1097/AOG.0b013e31820f387c.

9.

Changing depot medroxyprogesterone acetate access at a faith-based institution.

Guiahi M, McNulty M, Garbe G, Edwards S, Kenton K.

Contraception. 2011 Sep;84(3):280-4. doi: 10.1016/j.contraception.2010.12.003. Epub 2011 Feb 2.

PMID:
21843694
10.

Depo Provera. Position paper on clinical use, effectiveness and side effects.

Bigrigg A, Evans M, Gbolade B, Newton J, Pollard L, Szarewski A, Thomas C, Walling M.

Br J Fam Plann. 1999 Jul;25(2):69-76. Review. Erratum in: Br J Fam Plann 2000 Jan;26(1):52-3.

PMID:
10454658
11.

A systematic review of early postpartum medroxyprogesterone receipt and early breastfeeding cessation: evaluating the methodological rigor of the evidence.

Brownell EA, Fernandez ID, Howard CR, Fisher SG, Ternullo SR, Buckley RJ, Dozier AM.

Breastfeed Med. 2012 Feb;7(1):10-8. doi: 10.1089/bfm.2011.0105. Epub 2011 Nov 15. Review. Erratum in: Breastfeed Med. 2012 Apr;7(2):129.

12.

Weight and body fat changes in postpartum depot-medroxyprogesterone acetate users.

Nyirati CM, Habash DL, Shaffer LE.

Contraception. 2013 Jul;88(1):169-76. doi: 10.1016/j.contraception.2012.10.016. Epub 2012 Nov 21.

PMID:
23177262
13.

Bone mineral density in long-term depot medroxyprogesterone acetate acceptors.

Taneepanichskul S, Intaraprasert S, Theppisai U, Chaturachinda K.

Contraception. 1997 Jul;56(1):1-3.

PMID:
9306024
14.

Safety of the etonogestrel-releasing implant during the immediate postpartum period: a pilot study.

Brito MB, Ferriani RA, Quintana SM, Yazlle ME, Silva de Sá MF, Vieira CS.

Contraception. 2009 Dec;80(6):519-26. doi: 10.1016/j.contraception.2009.05.124. Epub 2009 Jul 10.

PMID:
19913145
15.

Subcutaneous DMPA vs. intramuscular DMPA: a 2-year randomized study of contraceptive efficacy and bone mineral density.

Kaunitz AM, Darney PD, Ross D, Wolter KD, Speroff L.

Contraception. 2009 Jul;80(1):7-17. doi: 10.1016/j.contraception.2009.02.005. Epub 2009 Mar 27.

PMID:
19501210
16.

Effectiveness of Cyclofem in the treatment of depot medroxyprogesterone acetate induced amenorrhea.

Piya-Anant M, Koetsawang S, Patrasupapong N, Dinchuen P, d'Arcangues C, Piaggio G, Pinol A.

Contraception. 1998 Jan;57(1):23-8.

PMID:
9554247
17.

Bone density in women receiving depot medroxyprogesterone acetate for contraception.

Cundy T, Evans M, Roberts H, Wattie D, Ames R, Reid IR.

BMJ. 1991 Jul 6;303(6793):13-6. Erratum in: BMJ 1991 Jul 27;303(6796):220.

18.

A cross-sectional study of the forearm bone mineral density in long-term current users of the injectable contraceptive depot medroxyprogesterone acetate.

Viola AS, Castro S, Bahamondes MV, Fernandes A, Viola CF, Bahamondes L.

Contraception. 2011 Nov;84(5):e31-7. doi: 10.1016/j.contraception.2011.06.012. Epub 2011 Aug 10.

PMID:
22018135
19.

Pilot study of home self-administration of subcutaneous depo-medroxyprogesterone acetate for contraception.

Cameron ST, Glasier A, Johnstone A.

Contraception. 2012 May;85(5):458-64. doi: 10.1016/j.contraception.2011.10.002. Epub 2011 Nov 12.

PMID:
22079602
20.

Self-administration of subcutaneous depot medroxyprogesterone acetate for contraception: feasibility and acceptability.

Prabhakaran S, Sweet A.

Contraception. 2012 May;85(5):453-7. doi: 10.1016/j.contraception.2011.09.015. Epub 2011 Nov 12.

PMID:
22079605
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk